Close window icon

3 INDICATIONS Otezla® (apremilast) is indicated for the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy.

Otezla is indicated for the treatment of adult patients with active psoriatic arthritis.

Otezla is indicated for the treatment of adult patients with oral ulcers associated with Behçet's Disease. Read less

Read less

Otezla is the first and only oral therapy approved across all severities of adult plaque psoriasis SEE THE DATA

Couple camping in the woods with their dog

OTEZLA® (APREMILAST) EFFICACY IN PLAQUE PSORIASIS

Otezla showed results across multiple endpoints at week 16 in patients with mild to moderate and moderate to severe plaque psoriasis 1,2

ADVANCE study design: A multicenter, randomized, placebo-controlled, double-blind study of biologic-naïve adults with mild to moderate plaque psoriasis. 3

ESTEEM 1 & 2 study designs: Two multicenter, double-blind, placebo-controlled trials of similar design for 1257 adult patients with moderate to severe plaque psoriasis. 1,4,5

STYLE study design: Phase 3, multicenter, randomized, double-blind, placebo-controlled study of 303 adult moderate to severe plaque psoriasis patients with moderate to severe plaque psoriasis of the scalp. 1

LIBERATE study design: Global, randomized, Phase 3b, placebo-controlled, double-blind, double-dummy study of 250 biologic-naïve patients with moderate to severe plaque psoriasis. 2

OTEZLA IS THE FIRST AND ONLY ORAL THERAPY
APPROVED ACROSS ALL SEVERITIES OF ADULT PLAQUE PSORIASIS

TREAT MULTIPLE MANIFESTATIONS OF PLAQUE PSORIASIS WITH OTEZLA 1,3,4,6

Chart of Otezla indicated to treat multiple manifestations, from mild to moderate and moderate to severe plaque psoriasis See sPGA Data Moderate See BSA-75 Data Moderate See SCALP Data Moderate See NAIL Data Moderate See ITCH Data Moderate See sPGA Data Severe See BSA-75 Data Severe See SCALP Data Severe See NAIL Data Severe See ITCH Data Severe Chart of Otezla indicated to treat multiple manifestations, from mild to moderate and moderate to severe plaque psoriasis See sPGA Data See BSA-75 Data See SCALP Data See Nail Data See ITCH Data See PASI-75 Data See Mean PASI Data See SCALP Data See NAIL Data See ITCH Data

*Efficacy of Otezla in nail psoriasis was studied in the ADVANCE clinical trial for patients with mild to moderate plaque psoriasis. Analysis is exploratory and has not been adjusted for multiple comparisons. No conclusions of statistical or clinical significance can be drawn.

MILD TO MODERATE PLAQUE PSORIASIS:

  • In ADVANCE, 22% of patients taking Otezla (n=297) achieved an sPGA score of 0 (clear) or 1 (almost clear) and a ≥2-point reduction from baseline vs 4% with placebo (n=298) at week 16 (P<0.0001; primary endpoint; ITT population) 1,3

MODERATE TO SEVERE PLAQUE PSORIASIS:

  • In ESTEEM 1, 33% of patients taking Otezla (n=562) achieved PASI-75 response vs 5% with placebo (n=282) at week 16 (P<0.0001; primary endpoint) 1,4
  • In ESTEEM 2, 29% of patients taking Otezla (n=274) achieved PASI-75 response vs 6% with placebo (n=137) at week 16 (P<0.001; primary endpoint) 5
  • In LIBERATE, 40% of patients taking Otezla (n=83) achieved PASI-75 response vs 12% with placebo (n=84) at week 16 (P<0.0001; primary endpoint) 2
  • In STYLE, 43% of patients taking Otezla (n=201) achieved a significant improvement in ScPGA response vs 14% with placebo (n=102) at week 16 (P<0.0001; primary endpoint; ITT population; MI analysis) 7
Thumbnail image for video of the Mechanism of Action in Plaque Psoriasis

Dermatology and
Multidisciplinary Care Videos

WATCH VIDEOS
Image of Otezla messaging as the number one prescribed systemic treatment for patients starting treatment for psoriasis

Otezla is the #1 prescribed brand for psoriasis patients starting systemic treatment 6,†

Image of Otezla messaging as the only oral therapy indicated for plaque psoriasis and psoriatic arthritis

The only oral therapy approved for all severities of adult plaque psoriasis and psoriatic arthritis

Based on IQVIA licensed data: Jan 2018 – Jun 2021 Longitudinal Prescription (LRx) Data and Medical Claims (Dx) Data, reflecting estimates of real-world activity. Study information maintained by Amgen. LRx Data covers retail, traditional/specialty mail order, and long-term claims. Dx data captures US physicians. Patient classified as systemic-naïve if not previously on systemic therapy for the past 12 months, had any claim for a branded systemic, and had at least one psoriasis diagnosis.

BSA, body surface area; ITT, intent to treat; MI, multiple imputation; PASI, Psoriasis Area and Severity Index; ScPGA, Scalp Physician Global Assessment; sPGA, static Physician Global Assessment.

close button

References: 1. National Psoriasis Foundation. psoriasis.org. Accessed February 21, 2021. 2. Nestle FO, Kaplan DH, Barker J. N Engl J Med. 2009;361(5):496-509. 3. Pariser D, Schenkel B, Carter C, et al. J Dermatolog Treat. 2016;27(1):19-26. 4. Mrowietz U, Kragballe K, Reich K, et al. Arch Dermatol Res. 2011;303(1):1-10. 5. Blakely K, Gooderham M. Psoriasis (Auckl). 2016;6:33-40. 6. Kimmel GW, Lebwohl M. Evidence-based Psoriasis: Diagnosis and Treatment. Springer; 2018:1-6. 7. Pasch MC. Drugs. 2016;76(6):675-705. 8. Van de Kerkhof PC, Reich K, Kavanaugh A, et al. J Eur Acad Dermatol Venereol. 2015;29(10):2002-2010. 9. Lebwohl MG, Kavanaugh A, Armstrong AW, Van Voorhees AS. Am J Clin Dermatol. 2016;17(1):87-97. 10. Kim WB, Jerome D, Yeung J. Can Fam Physician. 2017;63(4):278-285. 11. Van Voorhees AS, Feldman SR, Lebwohl MG, Mandelin A, Ritchlin C. The Psoriasis and Psoriatic Arthritis Pocket Guide. psoriasis.org/the-pocket-guide. Accessed July 19, 2021.

Accordion icon

IMPORTANT SAFETY INFORMATION

Contraindications

  • Otezla is contraindicated in patients with a known hypersensitivity to apremilast or to any of the excipients in the formulation

Warnings and Precautions

  • Hypersensitivity: Hypersensitivity reactions, including angioedema and anaphylaxis, have been reported during postmarketing surveillance. If signs or symptoms of serious hypersensitivity reactions occur, discontinue Otezla and institute appropriate therapy
  • Diarrhea, Nausea, and Vomiting: Cases of severe diarrhea, nausea, and vomiting were associated with the use of Otezla. Most events occurred within the first few weeks of treatment. In some cases, patients were hospitalized. Patients 65 years of age or older and patients taking medications that can lead to volume depletion or hypotension may be at a higher risk of complications from severe diarrhea, nausea, or vomiting. Monitor patients who are more susceptible to complications of diarrhea or vomiting; advise patients to contact their healthcare provider. Consider Otezla dose reduction or suspension if patients develop severe diarrhea, nausea, or vomiting
  • Depression: Carefully weigh the risks and benefits of treatment with Otezla for patients with a history of depression and/or suicidal thoughts/behavior, or in patients who develop such symptoms while on Otezla. Patients, caregivers, and families should be advised of the need to be alert for the emergence or worsening of depression, suicidal thoughts or other mood changes, and they should contact their healthcare provider if such changes occur
    • Plaque Psoriasis: Treatment with Otezla is associated with an increase in depression. During clinical trials in patients with moderate to severe plaque psoriasis, 1.3% (12/920) of patients reported depression compared to 0.4% (2/506) on placebo. Depression was reported as serious in 0.1% (1/1308) of patients exposed to Otezla, compared to none in placebo-treated patients (0/506). Suicidal behavior was observed in 0.1% (1/1308) of patients on Otezla, compared to 0.2% (1/506) on placebo. One patient treated with Otezla attempted suicide; one patient on placebo committed suicide
    • Psoriatic Arthritis: Treatment with Otezla is associated with an increase in depression. During clinical trials, 1.0% (10/998) reported depression or depressed mood compared to 0.8% (4/495) treated with placebo. Suicidal ideation and behavior was observed in 0.2% (3/1441) of patients on Otezla, compared to none in placebo-treated patients. Depression was reported as serious in 0.2% (3/1441) of patients exposed to Otezla, compared to none in placebo-treated patients (0/495). Two patients who received placebo committed suicide compared to none on Otezla
    • Behçet’s Disease: Treatment with Otezla is associated with an increase in depression. During the clinical trial, 1% (1/104) reported depression or depressed mood compared to 1% (1/103) treated with placebo. No instances of suicidal ideation or behavior were reported in patients treated with Otezla or treated with placebo
  • Weight Decrease: Monitor body weight regularly; evaluate unexplained or clinically significant weight loss, and consider discontinuation of Otezla
    • Plaque Psoriasis: Body weight loss of 5-10% occurred in 12% (96/784) of patients with moderate to severe plaque psoriasis treated with Otezla and in 5% (19/382) of patients treated with placebo. Body weight loss of ≥10% occurred in 2% (16/784) of patients treated with Otezla compared to 1% (3/382) of patients treated with placebo
    • Psoriatic Arthritis: Body weight loss of 5-10% was reported in 10% (49/497) of patients taking Otezla and in 3.3% (16/495) of patients taking placebo
    • Behçet’s Disease: Body weight loss of >5% was reported in 4.9% (5/103) of patients taking Otezla and in 3.9% (4/102) of patients taking placebo
  • Drug Interactions: Apremilast exposure was decreased when Otezla was co-administered with rifampin, a strong CYP450 enzyme inducer; loss of Otezla efficacy may occur. Concomitant use of Otezla with CYP450 enzyme inducers (e.g., rifampin, phenobarbital, carbamazepine, phenytoin) is not recommended

Adverse Reactions

  • Plaque Psoriasis: The most common adverse reactions (≥5%) are diarrhea, nausea, upper respiratory tract infection, and headache, including tension headache. Overall, the safety profile of Otezla in patients with mild to moderate plaque psoriasis was consistent with the safety profile previously established in adult patients with moderate to severe plaque psoriasis
  • Psoriatic Arthritis: The most common adverse reactions (≥5%) are diarrhea, nausea, and headache
  • Behçet’s Disease: The most common adverse reactions (≥10%) are diarrhea, nausea, headache, and upper respiratory tract infection

Use in Specific Populations

  • Otezla has not been studied in pregnant women. Advise pregnant women of the potential risk of fetal loss

Please click here for the full Prescribing Information.

INDICATIONS

Otezla® (apremilast) is indicated for the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy.

Otezla is indicated for the treatment of adult patients with active psoriatic arthritis.

Otezla is indicated for the treatment of adult patients with oral ulcers associated with Behçet’s Disease.

References: 1. Otezla [package insert]. Thousand Oaks, CA: Amgen Inc. 2. Reich K, Gooderham M, Green L, et al.. J Eur Acad Dermatol Venereol. 2017;31(3):507-517. 3. Stein Gold L, Papp K, Pariser D, et al. J Am Acad Dermatol. 2022;86(1):77-85. 4. Papp K, Reich K, Leonardi CL, et al. J Am Acad Dermatol. 2015;73(1):37-49. 5. Paul C, Cather J, Gooderham M, et al. Br J Dermatol. 2015;173(6):1387-1399. 6. Data on file, Amgen Inc. 7. Van Voorhees AS, Gold LS, Lebwohl M, et al. J Am Acad Dermatol. 2020;83(1):96-103.